Por favor, use este identificador para citar o enlazar este ítem:
http://conacyt.repositorioinstitucional.mx/jspui/handle/1000/895| The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro | |
| Caly, L Druce, J Catton, M Jans, D Wagstaff, K | |
| Acceso Abierto | |
| Atribución-NoComercial-SinDerivadas | |
| Highlights • Ivermectin is an inhibitor of the COVID-19 causative virus (SARS-CoV-2) in vitro. • A single treatment able to effect ∼5000-fold reduction in virus at 48h in cell culture. • Ivermectin is FDA-approved for parasitic infections, and therefore has a potential for repurposing. • Ivermectin is widely available, due to its inclusion on the WHO model list of essential medicines. | |
| Antiviral Research | |
| 2020 | |
| Preimpreso | |
| https://coronavirus.1science.com/item/c0a91f68843654a077a71104864bb4b162b369b0 | |
| Inglés | |
| VIRUS RESPIRATORIOS | |
| Aparece en las colecciones: | Artículos científicos |
Cargar archivos:
| Fichero | Tamaño | Formato | |
|---|---|---|---|
| 103361.pdf | 952.52 kB | Adobe PDF | Visualizar/Abrir |